Hallucinations and Delusions Treatment Market -t

Hallucinations and Delusions Treatment Market - Industry Trends and Forecast to 2027 with key players like ACADIA Pharmaceuticals Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, AbbVie Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., Bausch Health, Merck & Co., Inc

Hallucinations and Delusions Treatment Market By Types of Delusions (Erotomanic, Somatic, Persecutory and Others), Types of Hallucinations (Visual, Auditory, Olfactory and Others), Treatment Type (Conventional Antipsychotics, Atypical Antipsychotics and Others Medications), Route of Administration (Oral, Injectable and Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2027

Market Analysis: Global Hallucinations and Delusions Treatment Market

Global hallucinations and delusions treatment market is rising gradually with a substantial CAGR in the forecast period of 2021-2027. The report contains data of the base year 2019 and historic year 2018. Unmet need of medical therapies and increasing research and development of newer treatment options for hallucination and delusions are some factors that are expected to drive the market growth.

Download Full Sample Report Of  Hallucinations And Delusions Treatment Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hallucinations-and-delusions-treatment-market

Market Definition: Global Hallucinations and Delusions Treatment Market

Psychosis is a mental health problem that causes experience of things that do not exist or have no basis in reality. There are two main symptoms of psychosis that are hallucinations and delusions. Hallucinations are sensory experiences that occur without an actual stimulus. Delusions are the strong beliefs that are false and secret in the mind of the person having the delusion.

The prevalence of delusions and hallucinations is estimated to be 0.02%. Men are more likely to have paranoid delusions than women and in some cases like delusions of erotomania, the prevelance in women is higher. The rising occurrence of hallucinations and delusions in people and increasing geriatric population will drive the growth of global hallucination and delusions treatment market.

Market Drivers

Rising prevalence of parkinson's disease and its complications drives the global hallucination and delusions treatment market

Increasing geriatric population that are highly vulnerable for hallucinations and delusions will contribute in market growth

Unmet need of medical treatments for hallucinations and delusions is a potential driver of market growth

Increase in the rate of R&D initiatives fuels up the treatment market

Market Restraints

High cost therapies can impede the market growth

Lack of awareness about complications associated with hallucination and delusions obstructs the market growth

Segmentation: Global Hallucinations and Delusions Treatment Market

By Types of Delusions

·       Erotomanic

·       Somatic

·       Persecutory

·       Others

By Types of Hallucinations

·       Visual

·       Auditory

·       Olfactory

·       Others

By Treatment

·       Conventional Antipsychotics

·       Atypical Antipsychotics

·       Other Medications

By Route of Administration

·       Oral

·       Injectable

 By End Users

·       Hospitals

·       Homecare

·       Specialty Clinics

·       Others

By Distribution Channels

·       Hospital Pharmacy

·       Online Pharmacy

·       Retail Pharmacy

·       Others

By Geography

·       North America

·       U.S.

·       Canada

·       Mexico

·       Europe

·       Germany

·       Italy

·       U.K.

·       France

·       Spain

·       Netherlands

·       Belgium

·       Switzerland

·       Turkey

·       Russia

·       Hungary

·       Lithuania

·       Austria

·       Ireland

·       Norway

·       Poland

·       Rest of Europe

·       Asia-Pacific

·       Japan

·       China

·       India

·       South Korea

·       Australia

·       Singapore

·       Malaysia

·       Thailand

·       Indonesia

·       Philippines

·       Vietnam

·       Rest of Asia-Pacific

·       South America

·       Peru

·       Brazil

·       Argentina

·       Rest of South America

·       Middle East and Africa

·       South Africa

·       Saudi Arabia

·       UAE

·       Kuwait

·       Israel

·       Egypt

·       Israel

·       Rest of Middle East & Africa

Key Developments in the Market:

In September 2018, ACADIA Pharmaceuticals Inc. announced that the U. S. FDA issued a positive statement on Benefit-risk profile of Nuplazid (pimavanserin), a drug that is used for treatment of hallucination and delusions associated with Parkinson’s disease psychosis (PDP). This statement was based on a post marketing surveillance review of the drug. This positive statement resurrected the marketing of Nuplazid

In June 2018, ACADIA Pharmaceuticals Inc. received the U. S. FDA approval for a new formulation of Nuplazid (pimavanserin). Previously, nuplazid was recommended as two 17mg tablets. The new formulation is a 34 mg capsule single dose unit. This new dosage form of Nuplazid will reduce the pill burden maintaining the patient compliance

Competitive Analysis:

Global hallucinations and delusions treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of hallucinations and delusions treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global hallucinations and delusions treatment market are ACADIA Pharmaceuticals Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, AbbVie Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., Bausch Health, Merck & Co., Inc., Sanofi, Pfizer Inc., Johnson & Johnson Services, Inc., Mylan N.V., Alkermes, AstraZeneca, H. Lundbeck A/S, Cardinal Health, Autism Speaks Inc., Boehringer Ingelheim International GmbH, Mallinckrodt among others.

Get full details of TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hallucinations-and-delusions-treatment-market

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-hallucinations-and-delusions-treatment-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research 

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

Browse Related Reports @

Enhanced Vision System Market 

PDLC (Polymer Dispersed Liquid Crystal) for Smart Window Market